<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20240808001334&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20240808001334&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 08 Aug 2024 04:13:36 +0000</lastbuilddate>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Evaluating Pregnancy Safety During Cardiology Training</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2294. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39110472</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2294>10.1001/jamacardio.2024.2294</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110472</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Leila Haghighat</dc:creator>
<dc:creator>Shadi Kalantarian</dc:creator>
<dc:creator>Jacqueline T DesJardin</dc:creator>
<dc:creator>Cara N Pellegrini</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Evaluating Pregnancy Safety During Cardiology Training</dc:title>
<dc:identifier>pmid:39110472</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2294</dc:identifier>
</item>
<item>
<title>Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: After AMI, the risk of sudden death/RCA was highest in the first month, declining rapidly thereafter. Results revealed that compared with counterparts from 20 years ago, the rate of sudden death/RCA in patients with a reduced left ventricular ejection fraction and/or pulmonary congestion was 2- to 3-fold lower in people receiving contemporary management. Interventions to further protect people in the highest risk first month after infarction are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2356. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Sudden death is a leading cause of death after acute myocardial infarction (AMI). The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials enrolled patients with pulmonary congestion and/or left ventricular dysfunction after AMI. Whether the prognosis in such patients has changed over time has not been examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare the rate of sudden death/resuscitated cardiac arrest (RCA) after AMI in the PARADISE-MI and VALIANT trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of multicenter randomized clinical trials enrolling patients after AMI. In the primary analysis, the VALIANT cohort was restricted to patients with "PARADISE-MI-like" characteristics (eg, at least 1 augmenting risk factor and no history of heart failure). The baseline characteristics of people in both trials were compared. The VALIANT trial enrolled from December 1998 to June 2001, and the PARADISE-MI trial enrolled between December 2016, and March 2020. The median follow-up in the VALIANT and PARADISE-MI trials was 24.7 and 22 months, respectively. People with AMI, complicated by pulmonary congestion and/or left ventricular dysfunction, were included in the analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Sudden death after AMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 5661 patients were included in the PARADISE-MI cohort (mean [SD] age, 63.7 [11.5] years; 4298 male [75.9%]), 9617 were included in the VALIANT (PARADISE-MI-like) cohort (mean [SD] age, 66.1 [11.5] years; 6504 male [67.6%]), and 14 703 patients were included in the VALIANT (total) cohort (mean [SD] age, 64.8 [11.8] years; 10 133 male [68.9%]). In the PARADISE-MI-like cohort of the VALIANT trial, 707 of 9617 participants (7.4%) experienced sudden death/RCA. A total of 148 of 5661 people (2.6%) in the PARADISE-MI trial experienced sudden death/RCA. Sudden death rates were highest in the first month after infarction in both trials: 19.3 (95% CI, 16.4-22.6) per 100 person-years in the VALIANT trial and 9.5 (95% CI, 7.0-12.7) per 100 person-years in the PARADISE-MI trial, and these rates declined steadily thereafter. Compared with the VALIANT cohort, people in the PARADISE-MI trial were more often treated with percutaneous coronary intervention for their qualifying AMI and received a β-blocker, statin, and mineralocorticoid receptor antagonist more frequently.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: After AMI, the risk of sudden death/RCA was highest in the first month, declining rapidly thereafter. Results revealed that compared with counterparts from 20 years ago, the rate of sudden death/RCA in patients with a reduced left ventricular ejection fraction and/or pulmonary congestion was 2- to 3-fold lower in people receiving contemporary management. Interventions to further protect people in the highest risk first month after infarction are needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02924727.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39110471</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2356>10.1001/jamacardio.2024.2356</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110471</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>James P Curtain</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Doug L Mann</dc:creator>
<dc:creator>Jean L Rouleau</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Peter V Finn</dc:creator>
<dc:creator>Alberto Fernandez</dc:creator>
<dc:creator>Karola S Jering</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials</dc:title>
<dc:identifier>pmid:39110471</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2356</dc:identifier>
</item>
<item>
<title>Changing the Frame of Post-AMI Left Ventricular Dysfunction: Sudden Cardiac Death, a Diminishing Complication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2362. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39110452</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2362>10.1001/jamacardio.2024.2362</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110452</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Kristen K Patton</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Changing the Frame of Post-AMI Left Ventricular Dysfunction: Sudden Cardiac Death, a Diminishing Complication</dc:title>
<dc:identifier>pmid:39110452</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2362</dc:identifier>
</item>
<item>
<title>Progressive Cardiogenic Shock After Catheter Ablation in a Man Aged 78 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2199. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39110449</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2199>10.1001/jamacardio.2024.2199</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110449</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Karim Benali</dc:creator>
<dc:creator>Benjamin Seguy</dc:creator>
<dc:creator>Frederic Sacher</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Progressive Cardiogenic Shock After Catheter Ablation in a Man Aged 78 Years</dc:title>
<dc:identifier>pmid:39110449</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2199</dc:identifier>
</item>
<item>
<title>The Urgent Need to Improve Outcomes for Pregnant Cardiovascular Trainees</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110447/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2318. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110447/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39110447</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2318>10.1001/jamacardio.2024.2318</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110447</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Kristen K Patton</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Urgent Need to Improve Outcomes for Pregnant Cardiovascular Trainees</dc:title>
<dc:identifier>pmid:39110447</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2318</dc:identifier>
</item>
<item>
<title>Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This was a small, randomized clinical trial comparing different antithrombotic strategies after LAAO. Results show that use of low-dose DOAC for 3 months after LAAO was associated with a better balance between efficacy and safety compared with DAPT. However, the results of the study should be interpreted with caution due to the limited sample size and will need to be confirmed in future larger randomized trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2335. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Optimal antithrombotic therapy after percutaneous left atrial appendage occlusion (LAAO) is not well established as no randomized evaluation has been performed to date.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare the efficacy and safety of low-dose direct oral anticoagulation (low-dose DOAC) vs dual antiplatelet therapy (DAPT) for 3 months after LAAO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The ADALA (Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion) study was an investigator-initiated, multicenter, prospective, open-label, randomized clinical trial enrolling participants from June 12, 2019, to August 28, 2022 from 3 European sites. Patients who underwent successful LAAO were randomly assigned 1:1 to low-dose DOAC vs DAPT for 3 months after LAAO. The study was prematurely terminated when only 60% of the estimated sample size had been included due to lower recruitment rate than anticipated due to the COVID-19 pandemic.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: The low-dose DOAC group received apixaban, 2.5 mg every 12 hours, and the DAPT group received aspirin, 100 mg per day, plus clopidogrel, 75 mg per day, for the first 3 months after LAAO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was a composite of safety (major bleeding) and efficacy (thromboembolic events including stroke, systemic embolism, and device-related thrombosis [DRT]) within the first 3 months after successful LAAO. Secondary end points included individual components of the primary outcome and all-bleeding events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 90 patients (mean [SD] age, 76.6 [8.1] years; 60 male [66.7%]; mean [SD] CHADS-VASc score, 4.0 [1.5]) were included in the analysis (44 and 46 patients in the low-dose DOAC and DAPT groups, respectively). A total of 53 patients (58.8%) presented with previous major bleeding events (60 gastrointestinal [66.7%] and 16 intracranial [17.8%]). At 3 months, low-dose DOAC was associated with a reduction of the primary end point compared with DAPT (2 [4.5%] vs 10 [21.7%]; hazard ratio, 0.19; 95% CI, 0.04-0.88; P = .02). Patients in the low-dose DOAC group exhibited a lower rate of DRT (0% vs 6 [8.7%]; P = .04) and tended to have a lower incidence of major bleeding events (2 [4.6%] vs 6 [13.0%]; P = .17), with no differences in thromboembolic events such as stroke and systemic embolism between groups (none in the overall population).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This was a small, randomized clinical trial comparing different antithrombotic strategies after LAAO. Results show that use of low-dose DOAC for 3 months after LAAO was associated with a better balance between efficacy and safety compared with DAPT. However, the results of the study should be interpreted with caution due to the limited sample size and will need to be confirmed in future larger randomized trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05632445.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39110427</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2335>10.1001/jamacardio.2024.2335</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110427</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Xavier Freixa</dc:creator>
<dc:creator>Ignacio Cruz-González</dc:creator>
<dc:creator>Pedro Cepas-Guillén</dc:creator>
<dc:creator>Xavi Millán</dc:creator>
<dc:creator>Pablo Antúnez-Muiños</dc:creator>
<dc:creator>Eduardo Flores-Umanzor</dc:creator>
<dc:creator>Lluís Asmarats</dc:creator>
<dc:creator>Ander Regueiro</dc:creator>
<dc:creator>Sergio López-Tejero</dc:creator>
<dc:creator>Chi-Hion Pedro Li</dc:creator>
<dc:creator>Laura Sanchis</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Dabit Arzamendi</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39110427</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2335</dc:identifier>
</item>
<item>
<title>Rethinking Anticoagulation for Left Atrial Appendage Closure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110423/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2390. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110423/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39110423</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2390>10.1001/jamacardio.2024.2390</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110423</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:creator>Kristen K Patton</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Rethinking Anticoagulation for Left Atrial Appendage Closure</dc:title>
<dc:identifier>pmid:39110423</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2390</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: A reassuring answer to questions about statin therapy and diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39109935/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 7:ehae486. doi: 10.1093/eurheartj/ehae486. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39109935/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39109935</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae486>10.1093/eurheartj/ehae486</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39109935</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: A reassuring answer to questions about statin therapy and diabetes</dc:title>
<dc:identifier>pmid:39109935</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae486</dc:identifier>
</item>
<item>
<title>Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39109427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Although bystander CPR was associated with higher survival in all patients, its association with survival was weakest for Black individuals and women with out-of-hospital cardiac arrest.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 7. doi: 10.1161/CIRCULATIONAHA.124.068732. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Bystander cardiopulmonary resuscitation (CPR) is associated with higher survival for out-of-hospital cardiac arrest, but whether its association with survival differs by patients' sex and race and ethnicity is less clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Within a large US registry, we identified 623 342 nontraumatic out-of-hospital cardiac arrests during 2013 to 2022 for this observational cohort study. Using hierarchical logistic regression, we examined whether there was a differential association between bystander CPR and survival outcomes by patients' sex and race and ethnicity, overall and by neighborhood strata.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Mean age was 62.1±17.1 years, and 35.9% were women. Nearly half of patients (49.8%) were non-Hispanic White; 20.6% were non-Hispanic Black; 7.3% were Hispanic; 2.9% were Asian; and 0.4% were Native American. Overall, 58 098 (9.3%) survived to hospital discharge. Although bystander CPR was associated with higher survival in each race and ethnicity group, the association of bystander CPR compared with patients without bystander CPR in each racial and ethnic group was highest in individuals who were White (adjusted odds ratio [OR], 1.33 [95% CI, 1.30-1.37]) and Native American (adjusted OR, 1.40 [95% CI, 1.02-1.90]) and lowest in individuals who were Black (adjusted OR, 1.09 [95% CI, 1.04-1.14]; <i>P</i><sub>interaction</sub>&lt;0.001). The adjusted OR for bystander CPR compared with those without bystander CPR for Hispanic patients was 1.29 (95% CI, 1.20-1.139), for Asian patients, it was 1.27 (95% CI, 1.12-1.42), and for those of unknown race, it was 1.31 (95% CI, 1.25-1.36). Similarly, bystander CPR was associated with higher survival in both sexes, but its association with survival was higher in men (adjusted OR, 1.35 [95% CI, 1.31-1.38]) than women (adjusted OR, 1.15 [95% CI, 1.12-1.19]; <i>P</i><sub>interaction</sub>&lt;0.001). The weaker association of bystander CPR in Black individuals and women was consistent across neighborhood race and ethnicity and income strata. Similar results were observed for the outcome of survival without severe neurological deficits.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although bystander CPR was associated with higher survival in all patients, its association with survival was weakest for Black individuals and women with out-of-hospital cardiac arrest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39109427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39109427</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068732>10.1161/CIRCULATIONAHA.124.068732</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39109427</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul S Chan</dc:creator>
<dc:creator>Saket Girotra</dc:creator>
<dc:creator>Audrey Blewer</dc:creator>
<dc:creator>Kevin F Kennedy</dc:creator>
<dc:creator>Bryan F McNally</dc:creator>
<dc:creator>Justin L Benoit</dc:creator>
<dc:creator>Monique A Starks</dc:creator>
<dc:creator>CARES Surveillance Group</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest</dc:title>
<dc:identifier>pmid:39109427</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068732</dc:identifier>
</item>
<item>
<title>A heavy ball: the rare giant right coronary artery aneurysm with thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39108226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 7:ehae484. doi: 10.1093/eurheartj/ehae484. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39108226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39108226</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae484>10.1093/eurheartj/ehae484</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39108226</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Shuang Wang</dc:creator>
<dc:creator>Wanwan Song</dc:creator>
<dc:creator>Bin Wang</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A heavy ball: the rare giant right coronary artery aneurysm with thrombosis</dc:title>
<dc:identifier>pmid:39108226</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae484</dc:identifier>
</item>
<item>
<title>The FXR1 network acts as a signaling scaffold for actomyosin remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39106863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>It is currently not known whether mRNAs fulfill structural roles in the cytoplasm. Here, we report the fragile X-related protein 1 (FXR1) network, an mRNA-protein (mRNP) network present throughout the cytoplasm, formed by FXR1-mediated packaging of exceptionally long mRNAs. These mRNAs serve as an underlying condensate scaffold and concentrate FXR1 molecules. The FXR1 network contains multiple protein binding sites and functions as a signaling scaffold for interacting proteins. We show that it...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 31:S0092-8674(24)00775-X. doi: 10.1016/j.cell.2024.07.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">It is currently not known whether mRNAs fulfill structural roles in the cytoplasm. Here, we report the fragile X-related protein 1 (FXR1) network, an mRNA-protein (mRNP) network present throughout the cytoplasm, formed by FXR1-mediated packaging of exceptionally long mRNAs. These mRNAs serve as an underlying condensate scaffold and concentrate FXR1 molecules. The FXR1 network contains multiple protein binding sites and functions as a signaling scaffold for interacting proteins. We show that it is necessary for RhoA signaling-induced actomyosin reorganization to provide spatial proximity between kinases and their substrates. Point mutations in FXR1, found in its homolog FMR1, where they cause fragile X syndrome, disrupt the network. FXR1 network disruption prevents actomyosin remodeling-an essential and ubiquitous process for the regulation of cell shape, migration, and synaptic function. Our findings uncover a structural role for cytoplasmic mRNA and show how the FXR1 RNA-binding protein as part of the FXR1 network acts as an organizer of signaling reactions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39106863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39106863</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.015>10.1016/j.cell.2024.07.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39106863</guid>
<pubDate>Tue, 06 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiuzhen Chen</dc:creator>
<dc:creator>Mervin M Fansler</dc:creator>
<dc:creator>Urška Janjoš</dc:creator>
<dc:creator>Jernej Ule</dc:creator>
<dc:creator>Christine Mayr</dc:creator>
<dc:date>2024-08-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The FXR1 network acts as a signaling scaffold for actomyosin remodeling</dc:title>
<dc:identifier>pmid:39106863</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.015</dc:identifier>
</item>
<item>
<title>Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39106857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The HFA-ICOS score effectively categorizes patients by cardiovascular toxicity risk and demonstrates strong predictive ability for high-risk anthracycline-related cardiovascular toxicity and all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 6:ehae496. doi: 10.1093/eurheartj/ehae496. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Baseline cardiovascular toxicity risk stratification is critical in cardio-oncology. The Heart Failure Association (HFA) and International Cardio-Oncology Society (ICOS) score aims to assess this risk but lacks real-life validation. This study validates the HFA-ICOS score for anthracycline-induced cardiovascular toxicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Anthracycline-treated patients in the CARDIOTOX registry (NCT02039622) were stratified by the HFA-ICOS score. The primary endpoint was symptomatic or moderate to severe asymptomatic cancer therapy-related cardiac dysfunction (CTRCD), with all-cause mortality and cardiovascular mortality as secondary endpoints.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis included 1066 patients (mean age 54 ± 14 years; 81.9% women; 24.5% ≥65 years). According to the HFA-ICOS criteria, 571 patients (53.6%) were classified as low risk, 333 (31.2%) as moderate risk, 152 (14.3%) as high risk, and 10 (0.9%) as very high risk. Median follow-up was 54.8 months (interquartile range 24.6-81.8). A total of 197 patients (18.4%) died, and 718 (67.3%) developed CTRCD (symptomatic: n = 45; moderate to severe asymptomatic: n = 24; and mild asymptomatic: n = 649). Incidence rates of symptomatic or moderate to severe symptomatic CTRCD and all-cause mortality significantly increased with HFA-ICOS score [hazard ratio 28.74, 95% confidence interval (CI) 9.33-88.5; P &lt; .001, and hazard ratio 7.43, 95% CI 3.21-17.2; P &lt; .001) for very high-risk patients. The predictive model demonstrated good calibration (Brier score 0.04, 95% CI 0.03-0.05) and discrimination (area under the curve 0.78, 95% CI 0.70-0.82; Uno's C-statistic 0.78, 95% CI 0.71-0.84) for predicting symptomatic or severe/moderate asymptomatic CTRCD at 12 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The HFA-ICOS score effectively categorizes patients by cardiovascular toxicity risk and demonstrates strong predictive ability for high-risk anthracycline-related cardiovascular toxicity and all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39106857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39106857</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae496>10.1093/eurheartj/ehae496</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39106857</guid>
<pubDate>Tue, 06 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Borja Rivero-Santana</dc:creator>
<dc:creator>Jesús Saldaña-García</dc:creator>
<dc:creator>Juan Caro-Codón</dc:creator>
<dc:creator>Pilar Zamora</dc:creator>
<dc:creator>Pedro Moliner</dc:creator>
<dc:creator>Amparo Martínez Monzonis</dc:creator>
<dc:creator>Eduardo Zatarain</dc:creator>
<dc:creator>Carlos Álvarez-Ortega</dc:creator>
<dc:creator>Pilar Gómez-Prieto</dc:creator>
<dc:creator>Sonia Pernas</dc:creator>
<dc:creator>Isabel Rodriguez</dc:creator>
<dc:creator>Antonio Buño Soto</dc:creator>
<dc:creator>Rosalía Cadenas</dc:creator>
<dc:creator>Patricia Palacios Ozores</dc:creator>
<dc:creator>Sara Pérez Ramírez</dc:creator>
<dc:creator>María Merino Salvador</dc:creator>
<dc:creator>Silvia Valbuena</dc:creator>
<dc:creator>Lucía Fernández Gasso</dc:creator>
<dc:creator>Victor Juárez</dc:creator>
<dc:creator>Andrea Severo</dc:creator>
<dc:creator>Belén Terol</dc:creator>
<dc:creator>Teresa de Soto Álvarez</dc:creator>
<dc:creator>Olaia Rodríguez</dc:creator>
<dc:creator>María Brion</dc:creator>
<dc:creator>José González-Costello</dc:creator>
<dc:creator>Miguel Canales Albendea</dc:creator>
<dc:creator>José R González-Juanatey</dc:creator>
<dc:creator>Raúl Moreno</dc:creator>
<dc:creator>José López-Sendón</dc:creator>
<dc:creator>Teresa López-Fernández</dc:creator>
<dc:date>2024-08-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score</dc:title>
<dc:identifier>pmid:39106857</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae496</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: incremental utility of circulating biomarkers for cardiovascular risk prediction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39106856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 6:ehae481. doi: 10.1093/eurheartj/ehae481. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39106856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39106856</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae481>10.1093/eurheartj/ehae481</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39106856</guid>
<pubDate>Tue, 06 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-08-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: incremental utility of circulating biomarkers for cardiovascular risk prediction</dc:title>
<dc:identifier>pmid:39106856</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae481</dc:identifier>
</item>
<item>
<title>Combining 4D flow magnetic resonance imaging with cardiac catheterization for pre-operative blood flow assessment in an older child with complex congenital heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39106855/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 6:ehae488. doi: 10.1093/eurheartj/ehae488. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39106855/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39106855</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae488>10.1093/eurheartj/ehae488</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39106855</guid>
<pubDate>Tue, 06 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Wei Bai</dc:creator>
<dc:creator>Shuhua Luo</dc:creator>
<dc:creator>Huayan Xu</dc:creator>
<dc:date>2024-08-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Combining 4D flow magnetic resonance imaging with cardiac catheterization for pre-operative blood flow assessment in an older child with complex congenital heart disease</dc:title>
<dc:identifier>pmid:39106855</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae488</dc:identifier>
</item>
<item>
<title>Monocyte Single-Cell Multimodal Profiling in Cardiovascular Disease Risk States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39105287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This integrative and cross-species comparative analysis provides a new perspective on the comparison of alterations in monocytes in pathological conditions and offers insights into monocyte-driven mechanisms in cardiovascular disease and the potential for monocyte subpopulation targeted therapies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Aug 6. doi: 10.1161/CIRCRESAHA.124.324457. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Monocytes are a critical innate immune system cell type that serves homeostatic and immunoregulatory functions. They have been identified historically by the cell surface expression of CD14 and CD16. However, recent single-cell studies have revealed that they are much more heterogeneous than previously realized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We utilized cellular indexing of transcriptomes and epitopes by sequencing (cellular indexing of transcriptomes and epitopes by sequencing) and single-cell RNA sequencing to describe the comprehensive transcriptional and phenotypic landscape of 437 126 monocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This high-dimensional multimodal approach identified vast phenotypic diversity and functionally distinct subsets, including IFN-responsive, MHCII<sup>hi</sup>, monocyte-platelet aggregates, as well as nonclassical, sand several subpopulations of classical monocytes. Using flow cytometry, we validated the existence of MHCII<sup>+</sup>CD275<sup>+</sup> MHCII<sup>hi</sup>, CD42b<sup>+</sup> monocyte-platelet aggregates, CD16<sup>+</sup>CD99<sup>-</sup> nonclassical monocytes, and CD99<sup>+</sup> classical monocytes. Each subpopulation exhibited unique characteristics, developmental trajectories, transcriptional regulation, and tissue distribution. In addition, alterations associated with cardiovascular disease risk factors, including race, smoking, and hyperlipidemia were identified. Moreover, the effect of hyperlipidemia was recapitulated in mouse models of elevated cholesterol.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This integrative and cross-species comparative analysis provides a new perspective on the comparison of alterations in monocytes in pathological conditions and offers insights into monocyte-driven mechanisms in cardiovascular disease and the potential for monocyte subpopulation targeted therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39105287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39105287</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324457>10.1161/CIRCRESAHA.124.324457</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39105287</guid>
<pubDate>Tue, 06 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Bashore</dc:creator>
<dc:creator>Chenyi Xue</dc:creator>
<dc:creator>Eunyoung Kim</dc:creator>
<dc:creator>Hanying Yan</dc:creator>
<dc:creator>Lucie Y Zhu</dc:creator>
<dc:creator>Huize Pan</dc:creator>
<dc:creator>Michael Kissner</dc:creator>
<dc:creator>Leila S Ross</dc:creator>
<dc:creator>Hanrui Zhang</dc:creator>
<dc:creator>Mingyao Li</dc:creator>
<dc:creator>Muredach P Reilly</dc:creator>
<dc:date>2024-08-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Monocyte Single-Cell Multimodal Profiling in Cardiovascular Disease Risk States</dc:title>
<dc:identifier>pmid:39105287</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324457</dc:identifier>
</item>
<item>
<title>Correction to: ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102484/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):e151. doi: 10.1161/CIR.0000000000001280. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102484/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39102484</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001280>10.1161/CIR.0000000000001280</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102484</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial</dc:title>
<dc:identifier>pmid:39102484</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001280</dc:identifier>
</item>
<item>
<title>Eicosapentanoic Acid Supplementation for Atherosclerotic Cardiovascular Disease Prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102483/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):435-438. doi: 10.1161/CIRCULATIONAHA.124.069881. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102483/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39102483</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069881>10.1161/CIRCULATIONAHA.124.069881</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102483</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Vera Bittner</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Eicosapentanoic Acid Supplementation for Atherosclerotic Cardiovascular Disease Prevention</dc:title>
<dc:identifier>pmid:39102483</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069881</dc:identifier>
</item>
<item>
<title>Omega-3 Fatty Acids and Arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102482/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>The pro- and antiarrhythmic effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been extensively studied in preclinical and human trials. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit. Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):488-503. doi: 10.1161/CIRCULATIONAHA.123.065769. Epub 2024 Aug 5.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The pro- and antiarrhythmic effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been extensively studied in preclinical and human trials. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit. Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden cardiac death, but these findings have not been widely replicated, and the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to reduce arrhythmic death in combination, or as monotherapy, remains uncertain. The accumulated clinical evidence does not support supplementation of n-3 PUFA for postoperative AF or secondary prevention of AF. Several large, contemporary, randomized controlled trials of high-dose n-3 PUFA for primary or secondary cardiovascular prevention have demonstrated a small, significant, dose-dependent increased risk of incident AF compared with mineral oil or corn oil comparator. These findings were reproduced with both icosapent ethyl monotherapy and a mixed EPA+DHA formulation. The proarrhythmic mechanism of increased AF in contemporary cohorts exposed to high-dose n-3 PUFA is unknown. EPA and DHA and their metabolites have pleiotropic cardiometabolic and pro- and antiarrhythmic effects, including modification of the lipid raft microenvironment; alteration of cell membrane structure and fluidity; modulation of sodium, potassium, and calcium currents; and regulation of gene transcription, cell proliferation, and inflammation. Further characterization of the complex association between EPA, EPA+DHA, and DHA and AF is needed. Which formulations, dose ranges, and patient subgroups are at highest risk, remain unclear.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102482/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39102482</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065769>10.1161/CIRCULATIONAHA.123.065769</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102482</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mason D Marcus</dc:creator>
<dc:creator>Mark S Link</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Omega-3 Fatty Acids and Arrhythmias</dc:title>
<dc:identifier>pmid:39102482</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065769</dc:identifier>
</item>
<item>
<title>Recognition of an Unusual Pattern in a Case of Narrow Complex Tachycardia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102481/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):506-508. doi: 10.1161/CIRCULATIONAHA.124.070584. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102481/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39102481</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070584>10.1161/CIRCULATIONAHA.124.070584</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102481</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sudipta Mondal</dc:creator>
<dc:creator>Sreevilasam P Abhilash</dc:creator>
<dc:creator>Narayanan Namboodiri</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Recognition of an Unusual Pattern in a Case of Narrow Complex Tachycardia</dc:title>
<dc:identifier>pmid:39102481</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070584</dc:identifier>
</item>
<item>
<title>Retraction of: Abstract 18128: How Long Should We Tilt?: Challenging the 10-Minute Cutoff in the Diagnosis of Postural Tachycardia Syndrome (POTS)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):e152. doi: 10.1161/CIR.0000000000001279. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39102480</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001279>10.1161/CIR.0000000000001279</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102480</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Retraction of: Abstract 18128: How Long Should We Tilt?: Challenging the 10-Minute Cutoff in the Diagnosis of Postural Tachycardia Syndrome (POTS)</dc:title>
<dc:identifier>pmid:39102480</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001279</dc:identifier>
</item>
<item>
<title>Response by Chatur et al to Letter Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39102479/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240808001334&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 6;150(6):e107-e108. doi: 10.1161/CIRCULATIONAHA.124.069376. Epub 2024 Aug 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39102479/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240808001334&v=2.18.0.post9+e462414">39102479</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069376>10.1161/CIRCULATIONAHA.124.069376</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39102479</guid>
<pubDate>Mon, 05 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-08-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Chatur et al to Letter Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial"</dc:title>
<dc:identifier>pmid:39102479</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069376</dc:identifier>
</item>





























</channel>
</rss>